The authors comment on the direct reprogramming of stem cells for therapeutics. Topics covered include concerns that have restricted in vivo applications of tissues and organs to be recreated from embryonic stem cells, the limitations of induced stem cells as well as the complexity of reprogramming, and the stalled translation of direct reprogramming to the clinic.